Novartis reported 3.71B in Selling and Administration Expenses for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Abbvie ABBV:US $ 3.07B 228M
Alcon AG ALC:SW 783M 91M
Amgen AMGN:US $ 1.38B 130M
AstraZeneca AZN:LN 2.57B 76M
Bayer BAYN:GR 3.75B 226M
Biogen BIIB:US $ 637.3M 42.3M
Bristol Myers Squibb BMY:US $ 1.88B 215M
Eli Lilly And LLY:US $ 1.69B 109.7M
Fresenius FRE:GR 1.4B 134M
Fresenius Medical Care FME:GR 830M 118M
Galapagos GLPG:NA 60.95M 15.96M
Genmab GEN:DC 264M 63M
Gilead Sciences GILD:US $ 1.34B 297M
GlaxoSmithKline GSK:LN 2.5B 183M
GRIFOLS GRF:SM 249.86M 7.28M
H. Lundbeck A/S LUN:DC 1.58B 79M
Hikma Pharmaceutical HIK:LN 232M 3M
Johnson & Johnson JNJ:US $ 6.07B 641M
Merck MRK:GR 1.34B 62M
Merk MRK:US $ 2.25B 376M
Novartis NOVN:VX 3.71B 190M
Novartis NVS:US 3.71B 190M
Orion ORNBV:FH 60.1M 5.5M
Pfizer PFE:US $ 2.79B 134M
Philips PHIA:NA 1.19B 35M
Recordati REC:IM 117.42M 4.01M
Regeneron Pharmaceuticals REGN:US $ 414.7M 9.1M